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Abstract
Background: Fortification of human milk is a standard practice for feeding very low birth weight infants. However,
preterm infants often still experience suboptimal growth and feeding intolerance. New fortification strategies and
different commercially available fortifiers have been developed. Commercially available fortifiers are constituted by a
blend of ingredients from different sources, including plant oils and bovine milk proteins, thus presenting
remarkable differences in the quality of macronutrients with respect to human milk. Based on the consideration
that donkey milk has been suggested as a valid alternative for children allergic to cow’s milk proteins, due to its
biochemical similarity to human milk, we hypothesized that donkey milk could be a suitable ingredient for
developing an innovative human milk fortifier.
The aim of the study is to evaluate feeding tolerance, growth and clinical short and long-term outcomes in a
population of preterm infants fed with a novel multi-component fortifier and a protein concentrate derived from
donkey milk, in comparison to an analogous population fed with traditional fortifier and protein supplement
containing bovine milk proteins.
Methods: The study has been designed as a randomized, controlled, single-blind clinical trial. Infants born <1500 g
and <32 weeks of gestational age were randomized to receive for 21 days either a combination of control bovine
milk-based multicomponent fortifier and protein supplement, or a combination of a novel multicomponent fortifier
and protein supplement derived from donkey milk. The fortification protocol followed is the same for the two
groups, and the two diets were designed to be isoproteic and isocaloric. Weight, length and head circumference
are measured; feeding tolerance is assessed by a standardized protocol. The occurrence of sepsis, necrotizing
enterocolitis and adverse effects are monitored.
Discussion: This is the first clinical study investigating the use of a human milk fortifier derived from donkey milk
for the nutrition of preterm infants. If donkey milk derived products will be shown to improve the feeding tolerance
or either of the clinical, metabolic, neurological or auxological outcomes of preterm infants, it would be an absolute
innovation in the field of feeding practices for preterm infants.
Trial registration: ISRCTN -ISRCTN70022881.
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Background
Very preterm newborns (gestational age < 32 weeks) and
Very Low Birthweight Infants (VLBWI, birthweight
<1500 g) currently represent the majority of patients
assisted in Neonatal Intensive Care Units (NICU) [1]. The
increase of the survival rate for these newborns, due to
improvements in perinatal care, has opened new perspec-
tives regarding their outcome and has a significant impact
on their health status in adulthood.
Although very preterm or VLBWI usually attain some
“catch-up” growth following hospital discharge, growth def-
icits can persist throughout childhood and adolescence,
and into adulthood. Slow postnatal growth is associated
with neurodevelopmental impairment in later childhood,
with poorer cognitive outcomes, and may have conse-
quences for long-term metabolic and cardiovascular health
[2–4]. Nutrition represents a fundamental factor for long-
term survival and quality of life for this group of infants.
The main issue is to ensure an adequate qualitative and
quantitative nutrition, particularly in terms of protein in-
take, which is the main cause of post-natal growth deficit.
Human milk is the recommended form of enteral nutri-
tion for all neonates including preterm infants [5]. Breast
milk alone, however, does not meet the recommended nu-
tritional needs for growth in preterm infants [6, 7]. The
most common strategy in neonatal care facilities is to cope
with these potential nutrient deficits by supplementing
breast milk with additional nutrients (mainly proteins and
minerals) to ensure a sufficient caloric intake in consider-
ation of the special nutritional requirements [8–10]. The
fortification of human milk still represents a significant
challenge [11, 12]. The standard fortification strategies
have been considered unsatisfactory to sustain an appro-
priate growth. Thus, new approaches were developed,
among which Adjustable (ADJ) Fortification currently
seems to be the most promising [13]. It involves the use of
a protein supplement on an individualized basis, in
addition to a multi-component fortifier. This method, ac-
cepted at an international level, consists of providing a
variable protein intake based on the metabolic response of
each single newborn by titration to the infant’s blood urea
nitrogen level [14, 15]. This approach requires simple,
high-quality and well-tolerated protein supplements
which, unfortunately, are not readily available. Most com-
mercially available multi-nutrient fortifiers are derived
from bovine milk, which has a protein composition very
different from that of human milk. Moreover, cow milk
protein intake in the first months of life has raised con-
cerns because of its association with allergies [16] and
some studies have observed a possible role of cow’s milk
proteins as a trigger of intestinal inflammation in preterm
neonates. [17] Investigations on exclusive HM diets (hu-
man milk-based fortifier and donor HM, if mother’s milk
unavailable) have been carried out in recent years. All
these studies recently underwent to a systematic review
[18]; most of them were retrospective studies and not ran-
domized clinical trials. Authors conclude that there is not
strong evidence that human milk based fortifiers in other-
wise exclusively human milk-fed preterm infants affect
important outcomes. Consistently, milk from mono-
gastric animals, rather than from ruminants, has been sug-
gested during recent years to be more suitable for human
nutrition based on their physiochemical properties [19]. In
previous studies, our group observed on children affected
by cow milk protein allergy that donkey milk (DM) was
highly tolerated [20], and found that its protein and lipid
fractions showed a substantial similarity to that of human
milk [21, 22]. DM has an n-3 PUFA (polyunsaturated fatty
acids) content equivalent to human milk, and is rich in
lysozyme, a protein characterized by antibacterial proper-
ties, able to hinder pathogen growth, and milk spoilage. It
has been recently demonstrated in murine models that a
supplementation of the basal diet with DM decreases the
accumulation of body lipids and affects glucose and lipid
metabolism in a manner more similar to human milk than
cow milk [23] These biological effects resulted comparable
with those elicited by human milk [24] Based on the above
considerations, it can be speculated that DM is more suit-
able than bovine milk to be an ingredient of a human milk
fortifier for VLBW Infants and preterm newborns.
Our hypothesis is that feeding these newborns accord-
ing to ADJ fortification principles, with human milk for-
tified by protein and multi-component supplements
derived from DM, will improve the feeding tolerance
and the clinical, metabolic, neurological and auxological
outcome at short- and long-term.
We present the protocol of a study aimed to evaluate
the use of DM-derived multi-component fortifier and
protein concentrate for the nutrition of infants with
birthweight <1500 g or gestational age < 32 weeks. This
evaluation is being performed through a clinical trial
(randomized, controlled, blind) by comparing it with
commercial bovine milk-based multi-component fortifier
and protein concentrate.
Methods/design
The study is currently underway at the Neonatal Intensive
Care Unit (NICU) of the University of Turin, and has
been approved by Local Ethic Committee. Informed writ-
ten consent is obtained from parents before enrollment.
The trial was registered on ISRCTN Registry BioMed
Central (Registration number: ISRCTN70022881).
Study population
All patients admitted to our unit that met the follow-
ing inclusion criteria were consecutively enrolled in
the study.
Inclusion criteria:
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 Gestational age < 32 weeks or birthweight <1500 g
 Exclusive feeding with human milk (fresh own
mother’s or donor milk)
 Human milk volume > 80 ml/kg/day within the first
4 weeks of life
Exclusion criteria:
 Severe gastrointestinal pathologies (diagnosed or
suspected necrotizing enterocolitis, colostomy,
intestinal obstruction, symptoms of peritonitis,
presence of blood in the feces)
 Chromosomal abnormalities or major malformations
 Hereditary metabolic diseases
 Intravascular disseminated coagulopathy (IDC),
shock
 Patent Ductus Arteriosus (PDA) requiring medical
care or surgery at time of randomization
 Severe renal failure (serum creatinine >2 mg/dl)
Study design
Infants meeting inclusion criteria are identified and their
parents approached for consent. After informed written
parental consent is obtained, infants are randomized 1:1 by
a software-generated list in one of the following groups:
 Control group: Adjustable Fortification with
commercial multi-component fortifier (FM85
Nestlè) and protein concentrate (Protifar Nutri-
cia), named BMC and BPC respectively, derived
from bovine milk, for a minimum of 21 days (if
necessary, fortification is continued after this
period using the same type of product)
 Fortilat group: Adjustable Fortification with multi-
component fortifier and protein concentrate derived
from donkey milk, named DMC and DPC respect-
ively, not commercially available, and prepared ac-
cording to current EU legislation on Foods for
special medical purposes, for a minimum of 21 days
(if necessary, fortification is continued after this
period using the same type of product).
The composition of BMC and DMC are provided in
Table 1. Table 2 presents the composition of BPC and
DPC. The experimental products were produced by
ultrafiltration of pasteurized donkey milk in a pilot stain-
less steel plant. Retentates from the ultrafiltration pro-
cesses were then pasteurized and aseptically lyophilized
and packed. All the batches used for the trial were ana-
lyzed for the microbiological and chemical profile and
complied with the safety criteria required by Italian le-
gislation. The products are stored at −80 °C until used.
A nutrition protocol following the criteria of ADJ for-
tification is being followed to ensure that fortification
advancement is consistent for all study participants. Ta-
bles 3 and 4 show the ADJ Fortification criteria for the
control products (BMC and BPC) and for the test prod-
ucts (DMC and DPC). Since the protein concentration
and energy content of the bovine milk based products
differ from the donkey milk based products, the
amounts of powder required to obtain the same level of
fortification are different depending on the product in
use (Table 4). Because the same nurses in charge of
feeds preparation and administration are also in charge
of evaluating signs of feeding tolerance, it is not pos-
sible to achieve a double blindness of the intervention.
As caregivers are aware of the group allocation of in-
fants, this is to be defined as a single-blind randomized
controlled trial.
Advancing of enteral feeds is strictly regulated ac-
cording to the feeding protocol adopted in our NICU,
based on the evaluation of signs of feeding intolerance
(available on demand to the authors). The criteria for
hospital discharge are uniform, i.e., satisfactory weight
gain while receiving full oral feeding, maintenance of
adequate thermal stability and resolution of acute med-
ical conditions.
Table 1 Macro-composition of the multi-component fortifiers
derived from bovine milk (BMC) and from donkey milk (DMC).
Values per 100 g of product
BMC DMC
Protein g (Nx6.25) 20.0 22.5
Carbohydrate g 66.0 59.0
of which:
Lactose g 6.0 59.0
Maltodextrine g 60.0 0.0
Fat g 0.4 3.6
Energy:
Kcal 385 390
kcal/g protein 18.8 15.6
Calcium mg 1500 938
Phosphate mg 900 734
Osmolality mOsm/Kg 453 441
Table 2 Composition of the protein concentrates derived from
bovine milk (BPC) and from donkey milk (DPC). Values per 100 g
of product
BPC DPC
Protein g (Nx6.25) 88.5 43
Carbohydrate g <1.5 33.5
Fat g ≤2.0 6.1
Energy Kcal 370 418
Calcium mg 1350 1650
Phosphate mg 700 1150
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Outcome measures
1. Primary Endpoint.
Occurrence of at least one episode of feeding
intolerance, defined as interruption of enteral
feeding for at least eight consecutive hours
during the observation period.
2. Secondary Endpoints.
2.1 Gastrointestinal outcomes: Number of feeding
intolerance episodes, number of feeding
interruption episodes (of any duration), total
hours of enteral feeding interruption, time
required to reach full enteral feeding (150 ml/
kg/day).
2.2 Gastric Emptying time (ultrasonic measurements
of the antral cross sectional area) [25, 26]: half-
time of gastric emptying (minutes) and time of
gastric emptying (minutes).
2.3 Esophageal impedance and pH monitoring (MII/
pH) [27, 28]: GER frequency (reflux events/h),
bolus reflux extent (number of channels), Bolus
clearance time (seconds), bolus exposure index
and reflux index (percentage).
2.4 Clinical outcomes: necrotizing enterocolitis,
suspected or confirmed sepsis, mortality,
hospital stay duration, intraventricular
hemorrhage, retinopathy of prematurity
(defined according to the Vermont Oxford
Network) [29].
2.5 Metabolic and auxological outcomes (as shown
in the synoptic table) (Table 5).
Sample size
The sample size has been determined based on the oc-
currence of primary endpoint (at least one episode of
interruption of enteral feeding ≥8 h). Based on the data
available in our NICU from the population of VLBWI or
preterm infants, about 45% of infants present at least
one interruption of enteral feeding ≥8 h.
In the hypothesis that the use of a better tolerated for-
tifier causes a 25% reduction in the frequency of the pri-
mary endpoint, and setting the risk of type I errors and
the power at the usual 5 and 80%, 62 newborns per
group have been considered as required.
Planned recruitment rate and compliance
In the year 2014, 115 infants less than 32 weeks gestation
and weighting less than 1500 g were admitted to our
NICU. Breastfeeding initiation rates with mothers’ own
milk or donor milk were around 90% in our nursery.
Therefore, around 100 infants per year were estimated to
be eligible for the study, with a recruitment rate higher
than 60%. We did not anticipate problems with compli-
ance. The majority of mothers visits their baby on a regu-
lar basis, hence they are easily approached for consent as
soon as the infant reaches the point to start fortification.
Blood sampling required by the study protocol is consist-
ent with the routine monitoring performed in our unit,
hence there is no supplementary inconvenience for the
patients and it is easily accepted by parents.
Data collection methods
In order to promote the data quality, it has been pro-
vided a training plan for the nurses and clinicians based
on fortification protocols and evaluation of feeding toler-
ance. Data are being collected according to the scheme
shown in the synoptic table of the study (Table 5).
Weight, length and head circumference measurements
are recorded at birth, and during the observation period
(weight: daily; length and head circumference: weekly),
at 36 ± 1 weeks of postmenstrual age, 40 ± 1 weeks of
postmenstrual age, at 6, 12 and 18 months of corrected
age. The collection of outcomes, baseline, and other trial
data are reported in the specific form by copying them
from the medical record at discharge of the newborn.
Estimated rate of loss to follow up
Our NICU is a tertiary level neonatal unit. Most babies
in the NICU stay until discharge from hospital. Very few
infants return to local hospitals prior to discharge home,
and it generally is very rare that they are transferred
prior to 35 weeks corrected gestational age. In addition,
all infants that meet inclusion criteria for the study are
planned to be followed until two years of age, as part of
our follow-up program. We therefore do not expect any
significant loss to follow up.
Table 3 Adjustable Fortification criteria based on weekly blood
urea nitrogen (BUN) values
BUN (blood urea nitrogen)
< 10 mg/dl Increase fortification by one level
10–16 mg/dl No change
> 16 mg/dl Decrease fortification by one level
Table 4 Amount of fortifer and protein supplement at the











2.5% 0.025 0.02 – –
4% 0.04 0.032 – –
5% 0.05 0.04 – –
5% +1 0.05 0.04 + 0.004 0.008
5% +2 0.05 0.04 + 0.008 0.016
5% +3 0.05 0.04 + 0.012 0.024
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Statistical analysis
The statistical analysis will be performed by the Medical
Statistics and Biometry Unit of the Clinical and Commu-
nity Sciences of the University of Milan.
At the end of the recruitment, the occurrence of the pri-
mary endpoint will be evaluated on the intention-to-treat
population (all randomized infants). The comparison be-
tween the two study groups will be performed with the
exact Fisher test. All secondary endpoints will be modelled
in the framework of generalised linear model [30] allowing,
when appropriate, for relevant covariates. The number of
episodes of feeding intolerance (0, 1 … k) will be modelled
as a Poisson variable. Total hours of enteral feeding inter-
ruption, time required to reach full enteral feeding, hospital
stay duration, gastric emptying time and MII/pH parame-
ters will be modelled (after proper scale transformation, if
required) as normal variables. The occurrence of clinical
outcomes, assesed as dychotomous variable (yes/no) will be
modelled as binomial variables. Metabolic and auxological
outcomes, which are repeatedly during study period, will be
modelled (after proper scale transformation, if required) as
normal variables, with a model allowing for repeated mea-
sures. All statistical models are fit with SAS software [31].
Discussion
We present the protocol of a study aimed to assess the ef-
fects of a new human milk fortifier derived from donkey
milk on VLBWI feeding tolerance and growth. To the best
Table 5 Synoptic table. T0: before starting the fortification; T1: day 7 after beginning the fortification (if level 3 of ADJ fortification)
or as soon as level 3 is reached; T2: day 14 since beginning of fortification; T3: day 21 since beginning of fortification
STUDY PERIOD
Enrolment Allocation Post-allocation Close-out




Full patient history collection X
Allocation X
Intervention:
BUN X X X X
Albumin X X X X
Creatinine X X X X
Calcium X X X X
Phosphate X X X X
Alkaline Phosphatase X X X X
Weight X X X X
Lenght X X X X
Head circumference X X X X
Plasma Aminoacids X X
Urine Aminoacids X X
Urinary Metabolomic Profile X X
Calprotectin X X
pH X X X X
BE X X X X
HCO3
− X X X X
MII/pH X
Gastric emptying time X
Assesments
List other data variables X
List other data variables X
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of our knowledge, this trial is unique, being the first study
that investigates the use of a human milk fortifier derived
from donkey milk for the nutrition of preterm and VLBWI.
In our trial all the infants received exclusively human
milk (Fresh own mother’s milk or Pasteurized donor
milk) without any preterm formula supplementation.
The trial of Sullivan, comparing a human milk based for-
tifier with a bovine milk based fortifier, included in the
group supplemented with the bovine fortifier also sub-
jects fed with preterm formula [32]. This represents a
confounding variable masking the effects of the two dif-
ferent fortifiers as a sole supplement of human milk.
If the donkey milk derived fortifier will be proved to im-
prove the feeding tolerance or some of the other outcomes
(clinical, metabolic, neurological or auxological) of very
preterm and VLBWI, it would be an absolute innovation
in the field of feeding practices for preterm infants.
A possible limitation of our study is that it has been
designed as a single-blind randomized controlled trial,
being the caregivers aware of infants’ allocation in the
study. To try to eliminate any possible bias, a protocol
about the evaluation of the signs of feeding intolerance
has been introduced in our unit before the beginning of
the study. A strict adhesion to the protocol was recom-
mended to all the nursing staff.
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